Amgen, UCB are back pitching once-rejected osteoporosis drug romo to the FDA — but big hurdles lie ahead
Romosozumab is back.
Almost exactly a year after Amgen $AMGN and its partners at UCB were handed a rejection on the osteoporosis drug, they’ve repackaged …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
